# Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear

> **Open Intelligence Dossier** · First detected: 2026-07-24 19:07 UTC · Category: Business

## Executive Summary
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Everyday Health and Yahoo Finance. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Everyday Health | Retatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxOcGlfUklOVTNDNEhzRjk5cjlfbFFudkllV0FtNEluTE5aZmJaTGU4MldOXzdCcFZLc3VmWlpTNzdoaWs3azgyek1mYUpQLUs2bzkxUGFvaVRZdDM0WlRNdGxvaXV3MXlEUkQwa051S1RreExXS0ZaeE9CZkFldlYybUpxUmdDQzZmYmN3LUpEYUFVRC1XRFh5Y2F3?oc=5) |
| Yahoo Finance | Another win for Lilly’s triple-g agonist in two more Phase III trials | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxPMjRWc1hSWDlhLUl4V04yZnE1TjlkWlEyWlhnUmJZX0lOU0tiU29CTzk0ZllQZTdadnRVdGlQTFNxdTZZOEJxR19YU1Vwc3RsWnpDQ2lxZC1sRnZ4WnRqenp6OXlxdDdXY3JRNm9hRXp3TTR2bXJ6cWlFTmJ5cUtRc2t0V2k4NDZNU2NaRU9MNE4?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-24/lilly-s-triple-g-drug-hits-22-6-weight-loss-but-impact-on-reducing-cardio-risk*